NKTR
Biotechnology · Healthcare
Head of Investor Relations
Head of Investor Relations
Nektar Therapeutics (NKTR)Equibles does not estimate personal net worth.
Get an email with a short summary when Nektar Therapeutics publishes a filing, an earnings call transcript or a press release.
Get NKTR alertsVivian Wu is recorded as Head of Investor Relations at Nektar Therapeutics (NKTR). Vivian Wu has spoken on 6 earnings calls and 2 other investor events across 1 company, most recently for Nektar Therapeutics on November 12, 2026. Nektar Therapeutics is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Nektar Therapeutics includes Howard Robin (CEO), Jillian Thomsen (CFO and Chief Accounting Officer), Linda Rubinstein (CFO) and 2 others.
“On today's call, you will hear from Howard Robin, our President and Chief Executive Officer, Dr. Mary Tagliaferri, our Chief Medical Officer, Dr. Jonathan Zaleski, our Chief Research and Development Officer, and Linda Rubenstein, our Chief Financial Officer.”
“Thank you for joining us today to discuss new data being presented at the EADV 2026 Congress.”
“On today's call, you will hear from Howard Robin, our President and Chief Executive Officer, Dr. Jonathan Zalewski, our Chief Research and Development Officer, and Sandra Gardner, our Chief Financial Officer.”
“Today, you will hear from Howard Robin, our President and Chief Executive Officer, Dr. John Zinczewski, our Chief Research and Development Officer, and Dr. Mary Tagliaferri, our Chief Medical Officer.”
“Today, you will hear from Howard W. Robin, our President and Chief Executive Officer; Dr. Jonathan Zalevsky, our Chief Research and Development Officer; and Sandra A. Gardiner, our Chief Financial Officer.”
NKTR
Biotechnology · Healthcare
Head of Investor Relations